Development and implementation of a performance improvement project in adult intensive care units: overview of the Improving Medicine Through Pathway Assessment of Critical Therapy in Hospital-Acquired Pneumonia (IMPACT-HAP) study

Table 2 Quality indicators during pre- and post-implementation of consensus pathway for managing pneumonia in the ICU

Quality indicator	Number/number evaluable ^a (%)		P- value
	Pre-implementation ( n = 274)	Post-implementation ( n = 158)
QI-1: Diagnostic criteria for HAP, VAP or HCAP met	247/257 (96.1)	150/151 (99.3)	0.06
QI-2a: Respiratory sample obtained before antibiotics	253/265 (95.5)	134/141 (95.0)	0.81
QI-2b: Blood culture obtained before antibiotics	214/264 (81.1)	121/141 (85.8)	0.23
QI-3: Empiric therapy compliant with ATS/IDSA guidelines [1]^b	79/257 (30.7)	66/151 (43.7)	0.01
QI-4: Short-course therapy performed	5/20 (25.0)	9/17 (52.9)	0.10
QI-5a: De-escalation possible	173/266 (65.0)	96/140 (68.6)	0.47
QI-5b: De-escalation possible and performed	56/173 (32.4)	36/96 (37.5)	0.40
QI-6: Clinical success at day 14	170/250 (68.0)	89/134 (66.4)	0.75

ATS, American Thoracic Society; HAP, hospital-acquired pneumonia; HCAP, healthcare-associated pneumonia; ICU, intensive care unit; IDSA, Infectious Diseases Society of America; VAP, ventilator-associated pneumonia.
^a All patients were not evaluable for every quality indicator. ^b Empiric therapy compliant with center-specific guidelines: pre- vs post-implementation, 92/257 (35.8%) vs 77/151 (51.0%); P = 0.002.

ISSN: 1364-8535